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Another STICH in the Shroud of Observation-Based Paradigm?*Marvin A. Konstam, MDF ollowing myocardial infarction, left ventri-cular (LV) remodeling is characterized by in-creased LV end-diastolic and end-systolic
volumes (ESV) and decreased LV ejection fraction
(EF) (1). This process is driven by elongation of
infarcted zones and changes within the unaffected
myocardium, including myocyte hypertrophy and
interstitial collagen deposition. With medical ther-
apy, revascularization, or cardiac resynchronization,
the probability of reversing this process is greater
where there is a greater proportion of viable myocar-
dium, as assessed by noninvasive imaging (2–4).
Based on a series of observational analyses (2,5,6),
the extent of viability has been used to predict a
greater LV functional beneﬁt and improved survival
from coronary artery bypass graft (CABG) versus med-
ical therapy. This practice is not supported by results
of a prior analysis of data from the randomized,
controlled STICH (Surgical Treatment for Systolic
Heart Failure) trial (7). However, additional studies
have suggested that LV functional improvement
following CABG is diminished in patients with greater
LV volumes (8,9). These ﬁndings suggest that CABG
may confer survival beneﬁt only among patients
with substantial viability, in the absence of severe
remodeling. A report by Bonow et al. (10) in this issue
of iJACC does not support this hypothesis, examiningSEE PAGE 1121survival among patients randomized to CABG versus
medical therapy alone in patients with myocardial
viability without severe LV ESV enlargement. In this
analysis, patients in the STICH trial who had viability
assessed and had substantial myocardial viability*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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disclose.with LV ESV #84 ml/m2 showed no survival beneﬁt
with CABG, compared with medical therapy alone,
similar to patients with larger LV ESV and similar to
the overall STICH population.
The extent of LV remodeling is a strong indepen-
dent predictor of survival, and LV volumes represent
the biomarker that comes closest to representing a
surrogate for mortality in patients with heart failure
and reduced LVEF, given the strong correlation be-
tween an intervention’s effects on LV volumes and on
mortality (11,12). It is reasonable to hypothesize that
in patients with more remodeling, there is less op-
portunity for reversal and therefore less opportunity
for improved survival with any intervention. Like-
wise, it is reasonable to hypothesize that an LV with
lesser degrees of viability represents a poorer sub-
strate for reversing remodeling and improving LV
function. Importantly, viability and remodeling are
not fully independent. Less viability is likely to be
associated with larger LV volumes.
In the STICH trial, there was no beneﬁt of ran-
domization to CABG, compared with medical therapy
alone, in patients with coronary artery disease
amenable to CABG and LVEF #35%, in the absence of
either left main coronary artery stenosis or Canadian
Cardiovascular Society class III or IV angina, despite
medical therapy (13). We have now learned that
these ﬁndings were consistent in a subgroup of pa-
tients with myocardial viability and a limited degree
of LV remodeling. There are 2 broad possibilities to
explain why ﬁndings from the STICH trial did not
substantiate those of the nonrandomized observa-
tional analyses.
The ﬁrst is that the absence of substantiation within
the STICH study results from discordance between
the STICH population and those of the observational
analyses. It may be difﬁcult to demonstrate beneﬁt
within a subgroup when the overall population
showed no beneﬁt. This combination would imply
an adverse effect of CABG in the remaining popula-
tion. The STICH population had characteristics that
may have limited the overall ability to demonstrate
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1131CABG beneﬁt, compared with the earlier analyses.
One difference is the greater background use of
contemporary treatments, including beta-blockers,
renin-angiotensin-aldosterone system inhibitors, and
implantable cardioverter-deﬁbrillators. These treat-
ments have many of the same beneﬁts expected
from CABG, including reversal of remodeling, pre-
vention of recurrent ischemic events, and prevention
of lethal arrhythmias. The mortality rate in the medi-
cal arm of the STICH trial (13) was lower than that
among patients showing myocardial viability and
treated medically across a meta-analysis of older
observational cohorts (2).
A second differential characteristic of the STICH
population is that patients believed to be most likely
to beneﬁt from CABG may have been selected out,
either by design or by clinician preference. Patients
with the highest grades of angina were excluded by
protocol, both for ethical reasons and because the
STICH hypothesis was that CABG would increase
survival even among patients in whom there was not
a clinical imperative toward surgery. Additionally,
investigators likely had pre-conceived opinions about
CABG beneﬁt, leading to exclusion of patients with
substantial ischemia on noninvasive imaging and
with more severe multivessel disease. Such patients
probably heavily populated the observational co-
horts, helping to drive CABG beneﬁt.
A second possible explanation for the absence of
corroboration by the STICH trial of earlier observations
is that the latter were inﬂuenced by either: 1) bias, as
occurs from nonrandomized treatment selection; and/
or 2) absence of an adequate control group. In patients
with greater viability and less remodeling, non-
randomized assignment to medical therapy may have
been on the basis of greater comorbidity, thus biasing
the result in favor of CABG. It is possible that in pa-
tients with less viability or greater remodeling, pa-
tients were less readily stratiﬁed according to othercomorbidities, so that CABG assignment was not as
biased in that respect. Without controls, it is possible
that the ﬁndings of dependence of LV functional
improvement with CABG on the absence of severe
remodeling might have been present without CABG.
The ﬁndings of Bonow et al. (10) may represent
another cautionary tale regarding conclusions of non-
randomized observational analyses. Adjustment for
covariate imbalance resulting through nonran-
domized treatment assignment is never complete. In
the STICH trial, randomization removes any pos-
sible selection bias. However, as opposed to other cir-
cumstances in which a primary endpoint ﬁnding of a
large randomized trial refuted a prior paradigm
(14), the present analysis was in post-hoc subsets,
drawn only from the cohort that underwent 1 of several
methods of viability assessment. Therefore, the anal-
ysis by Bonow et al. (10) cannot deﬁnitively refute prior
conclusions. The hypotheses generated by observa-
tional analyses are best tested primarily and prospec-
tively within randomized controlled trials.
We are now left less certain of the value of global
viability assessment, with or without LV volume
measurement, in predicting clinical beneﬁt from
CABG. There remains adequate rationale for matching
regional viability with coronary revascularization
targets as a means to guide decision making. Also,
given the nature of the present analysis, we cannot
rule out a value of deploying global viability assess-
ments for predicting CABG beneﬁt, particularly
within populations underrepresented in the STICH
trial. Nevertheless, these ﬁndings call for caution in
interpreting prior observational analyses used to
justify such practice.
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